Adeleke Halilu Aguda,^{a,b*}
Amos Malle Sakwe,^{a,†} Lars Rask^a
and Robert Charles Robinson^{a,b}

^aDepartment of Medical Biochemistry and
Microbiology, Uppsala University, Sweden, and
^bInstitute of Molecular and Cell Biology,
Singapore

[†] Present address: Department of Medical
Genetics and Microbiology, University of
Toronto, Canada.

Correspondence e-mail:
adelekeha@imcb.a-star.edu.sg

Received 2 November 2006
Accepted 8 February 2007

Expression, crystallization and preliminary crystallographic data analysis of filamin A repeats 14–16

Human filamin A is a 280 kDa protein involved in actin-filament cross-linking. It is structurally divided into an actin-binding headpiece (ABD) and a rod domain containing 24 immunoglobulin-like (Ig) repeats. A fragment of human filamin A (Ig repeats 14–16) was cloned and expressed in *Escherichia coli* and the purified protein was crystallized in 1.6 M ammonium sulfate, 2% PEG 1000 and 100 mM HEPES pH 7.5. The crystals diffracted to 1.95 Å and belong to space group $P2_12_12_1$, with unit-cell parameters $a = 50.63$, $b = 52.10$, $c = 98.46$ Å, $\alpha = \beta = \gamma = 90^\circ$.

1. Introduction

Actin-filament architecture and dynamics contribute to the morphology and motility of cells in processes that are tightly regulated by a vast and diverse set of actin-binding proteins (ABPs). The distinct properties of ABPs have allowed classification by function as capping, severing, nucleating, sequestering and cross-linking proteins. The mechanisms of action of members of several of these classes have been clarified by the elucidation of their X-ray structures in complex with actin. However, ABPs that cross-link filamentous actin (F-actin), including filamins, α -actinin and spectrin, have not been amenable to this approach owing to the implicit heterogeneity of F-actin.

Filamins were first discovered over 30 years ago as a group of F-actin cross-linking proteins that exist in *Dictyostelium*, chicken and mammals (Shizuta *et al.*, 1976; Wang *et al.*, 1975). In humans, three different filamin genes, *flna*, *flnb* and *finc*, have been identified, encoding the proteins filamins A, B and C, respectively. Filamins A and B are ubiquitously expressed (Gorlin *et al.*, 1990; Takafuta *et al.*, 1998), while filamin C is predominantly expressed in cardiac and skeletal muscles (Xie *et al.*, 1998). The filamins are 280 kDa proteins consisting of an N-terminal actin-binding domain (ABD) headpiece followed by a C-terminal rod region (Hock *et al.*, 1990). The ABD comprises tandem calponin-homology domains (CH1 and CH2) that are responsible for F-actin interaction. Each 110-residue CH domain consists of six or seven α -helices, four of which contain 11–18 residues. Filamin headpieces show sequence similarity to other α -actinin-like CH domains and are expected to adopt similar structures (Carugo *et al.*, 1997).

The rod region consists of repeating 100-residue immunoglobulin-like domains that are rich in β -structure. In human filamins there are 24 Ig-like domains; there are 20 in *Drosophila* and six in *Dictyostelium* (Fucini *et al.*, 1997; Popowicz *et al.*, 2006). Domain 24 in humans is able to homodimerize, which gives the filamin dimer a V-shape speculated to be crucial in F-actin cross-linking (Feng & Walsh, 2004; Pudas *et al.*, 2005; Weihing, 1988). The Ig-like domains are connected by short stretches of amino acids, with larger insertions between domains 15–16 and 23–24 that form hinges 1 and 2, respectively (Davies *et al.*, 1978; van der Flier & Sonnenberg, 2001). Filamins also interact with a number of transmembrane receptors that enable the actin cytoskeleton to respond to extracellular stimuli, thereby casting filamin as a scaffolding protein that bridges signalling to the cytoskeleton. Consequently, mutations in the filamin genes have been linked to various diseases, including periventricular heterotopia and the otopalatodigital (OPD) spectrum disorders (Fox *et al.*, 1998; Robertson *et al.*, 2003; Zenker *et al.*, 2004). Furthermore, aberrant

filamin cleavage is associated with several conditions, including Graves' disease, myasthenia gravis, glomerulonephritis and platelet activation (Leedman *et al.*, 1993; Peutz-Kootstra *et al.*, 2000; Yamamoto *et al.*, 1987).

Crystal structures of several Ig-like domains of human filamins have been reported, including domains 17, 21, 23 and 24. These structures have revealed the dimerization interface and the interactions with Von Willebrand factor (Nakamura *et al.*, 2006; Pudas *et al.*, 2005). However, these structures cover only a small proportion of the Ig-like domains and many more structures are required to provide a comprehensive description of the rod region and its interaction with binding partners. We have identified rod domains 14–16 of filamin A as a key region for structural characterization. This triplet of domains interacts with the extracellular calcium receptor (CaR), FILIP, TRAF 1 and 2 and FAP 52 and also contains the flexible hinge 1 (Awata *et al.*, 2001; Popowicz *et al.*, 2006; Taveau *et al.*, 2003). Here, we report the expression, purification, crystallization and preliminary crystallographic data analysis of filamin A repeats 14–16.

2. Materials and methods

2.1. Cloning, expression and purification

The DNA segment encoding human filamin A residues 1534–1875 was amplified from a human foetal kidney cDNA (Clontech). The 5'-

primer AAAGTCGACCCCTTCAAGGTCAAGGTG and 3'-primer AAAGCGGCCGCTTAGAGGCCAGGCCATA were used to amplify a 1 kbp PCR product that was inserted into the *SalI* and *NotI* sites of the pGEX-4T-3 plasmid (GE Healthcare). The DNA fragment was verified by DNA sequencing and subsequently transformed into *Escherichia coli* BL21 (DE3) expression cells (Invitrogen). The expressed protein has an N-terminal GST tag followed by a thrombin protease cleavage site and an extra PNSRVD linker between the thrombin cleavage site and the protein.

6 l LB medium supplemented with 100 µg ml⁻¹ ampicillin was inoculated with 300 ml of a fresh overnight culture and grown in a glass fermenter (Bellco Glass Inc., USA) at 310 K with stirring at 150 rev min⁻¹ until the OD₆₀₀ reached 0.8. Induction was achieved with 1 mM IPTG and expression was allowed to continue overnight at 303 K.

Cells were harvested by centrifugation in a Beckman J6-MI centrifuge at 4000 rev min⁻¹ for 45 min at 277 K. Pellets were resuspended in GST lysis buffer (50 mM Tris pH 7.6, 150 mM NaCl and 1 mM DTT) and frozen at 193 K. Pellets frozen in lysis buffer were thawed and further lysed by sonicating on ice using a Sonicator 3000 (Misonix Incorporated).

Cell debris was pelleted by centrifugation at 18 500 rev min⁻¹ in a Sorvall SA-300 rotor for 45 min at 277 K and the supernatant was further clarified by filtration through a 0.45 µm filter (Sartorius). The supernatant was then loaded onto an ÄKTA Xpress purification system (GE Healthcare) for passage through a GST-Trap FF 5 ml affinity column with thrombin (20 units per millilitre of beads) in GST-binding buffer (50 mM Tris pH 7.6, 150 mM NaCl and 1 mM DTT) for 10 h to remove the GST tag. The tag-free protein was then passed through a Hi-Prep 26/10 desalting column pre-equilibrated in 20 mM Tris pH 7.6 and a Resource Q anion exchanger (binding buffer, 20 mM Tris pH 7.6; elution buffer, 20 mM Tris pH 7.6, 1 M NaCl). A final Superdex 75 gel-filtration step was performed in 50 mM Tris pH 7.6, 150 mM NaCl (all columns were from GE Healthcare). Fractions containing filamin A repeats 14–16 were run on SDS-PAGE (Fig. 1) and those judged to be pure were subsequently pooled and concentrated to 10 mg ml⁻¹ with buffer exchange into 10 mM Tris pH 7.2, 50 mM NaCl using a 10 kDa cutoff Vivaspin membrane (Vivascience). The size on the gel corresponded to the expected 36.3 kDa tag-free protein. Prior to crystallization, the sample was checked for homogeneity by dynamic light scattering using a DynaPro MSX/TC Instrument (Protein Solutions Ltd).

Figure 1 SDS-PAGE showing tag-cleavage and gel-filtration fractions of human filamin A repeats 14–16. (a) Cleaved protein (lane 1), uncleaved protein (lane 2) and molecular-weight standards (lane 3) with sizes labelled in kDa. (b) Fractions from gel filtration (lanes 1–6) showing the 36.3 kDa protein and molecular-weight standards (lane 7).

Figure 2 Crystal (dimensions 0.3 × 0.2 × 0.05 mm) of filamin A repeats 14–16 in 1.6 M ammonium sulfate, 2% PEG 1000 and 100 mM HEPES pH 7.5. Although lacking distinct edges, this lens-shaped crystal diffracted to 1.7 Å.

Table 1

Statistics of preliminary data analysis.

Values in parentheses are for the highest resolution shell.

Resolution (Å)	24.62–1.95 (2.06–1.95)
Wavelength (Å)	1.5418
Unit-cell parameters (Å, °)	$a = 50.63$, $b = 52.10$, $c = 98.46$, $\alpha = \beta = \gamma = 90^\circ$
Space group	$P2_12_12_1$
Observed reflections	204864 (26685)
Unique reflections	18692 (2598)
R_{merge} (%)	0.071 (0.330)
Completeness (%)	95.4 (92.9)
Redundancy (%)	11.0 (10.3)

2.2. Crystallization and data collection

The search for crystallization conditions for concentrated filamin A repeats 14–16 was carried out *via* sitting-drop vapour-diffusion experiments with the aid of an Innovadyne 96+8 screenmaker (Innovadyne). 0.2 μ l protein solution was mixed with 0.2 μ l reservoir solution and equilibrated over 60 μ l reservoir solution. Plate-like crystals were observed in several conditions from Wizard (Emerald Biosciences) and JB HTS II L (Jena Bioscience) screens at 288 K.

For cryoprotection, the crystal was soaked in a cryosolution containing mother liquor supplemented with 15% glycerol for 30 s. The crystal was then quickly mounted and cryocooled in a nitrogen cryostream at 100 K on a Rigaku/MSF FR-E Superbright X-ray source operating at 40 kV and 80 mA with a copper anode. 280 image frames were collected (120 s exposure time per frame, 0.5° oscillations) to a resolution of 1.7 Å on an R-Axis IV⁺⁺ detector at a wavelength of 1.542 Å.

The collected data were indexed using *MOSFLM* (Collaborative Computational Project, Number 4, 1994) and scaling was carried out to 1.95 Å using *SCALA* (Collaborative Computational Project, Number 4, 1994).

3. Results and discussion

The DNA segment encoding human filamin A repeats 14–16 with an N-terminal GST tag was cloned and expressed in *E. coli* BL21 (DE3) cells. Crystals first appeared after four weeks of incubation at 288 K and grew to final dimensions of 0.3 × 0.2 × 0.05 mm over a further three weeks (Fig. 2). Data were collected from a crystal that grew in a well corresponding to 1.6 M ammonium sulfate, 2% PEG 1000 and 100 mM HEPES pH 7.5.

The space group was deduced to be $P2_12_12_1$, with unit-cell parameters $a = 50.63$, $b = 52.10$, $c = 98.46$ Å, $\alpha = \beta = \gamma = 90^\circ$. The unit-cell volume is 259 747 Å³ and one protein molecule is assumed per asymmetric unit (see Table 1).

The quality of the data indicates the possibility of solving the structure of filamin A repeats 14–16 by molecular replacement using the crystal structure of domain 24 of human filamin C (PDB code 1v05) as a start model in a multicopy search. We expect to achieve a solution from molecular replacement and refinement using the programs *AMoRe* and *REFMAC* v.5.0 (Collaborative Computational

Project, Number 4, 1994), respectively. Viewing of the molecule and manual rebuilding will be achieved with the aid of the program *O* (Jones *et al.*, 1991).

We are grateful to the Swedish Medical Science Research Council and A*STAR Singapore for financial support. The authors declare that they have no competing financial interests.

References

- Awata, H., Huang, C., Handlogten, M. E. & Miller, R. T. (2001). *J. Biol. Chem.* **276**, 34871–34879.
- Carugo, K. D., Banuelos, S. & Saraste, M. (1997). *Nature Struct. Biol.* **4**, 175–179.
- Collaborative Computational Project, Number 4 (1994). *Acta Cryst.* **D50**, 760–763.
- Davies, P. J., Wallach, D., Willingham, M. C., Pastan, I., Yamaguchi, M. & Robson, R. M. (1978). *J. Biol. Chem.* **253**, 4036–4042.
- Feng, Y. & Walsh, C. A. (2004). *Nature Cell Biol.* **6**, 1034–1038.
- Flier, A. van der & Sonnenberg, A. (2001). *Biochim. Biophys. Acta*, **1538**, 99–117.
- Fox, J. W., Lamperti, E. D., Eksioğlu, Y. Z., Hong, S. E., Feng, Y., Graham, D. A., Scheffer, I. E., Dobyns, W. B., Hirsch, B. A., Radtke, R. A., Berkovic, S. F., Huttenlocher, P. R. & Walsh, C. A. (1998). *Neuron*, **21**, 1315–1325.
- Fucini, P., Renner, C., Herberhold, C., Noegel, A. A. & Holak, T. A. (1997). *Nature Struct. Biol.* **4**, 223–230.
- Gorlin, J. B., Yamin, R., Egan, S., Stewart, M., Stossel, T. P., Kwiatkowski, D. J. & Hartwig, J. H. (1990). *J. Cell Biol.* **111**, 1089–1105.
- Hock, R. S., Davis, G. & Speicher, D. W. (1990). *Biochemistry*, **29**, 9441–9451.
- Jones, T. A., Zou, J.-Y., Cowan, S. W. & Kjeldgaard, M. (1991). *Acta Cryst.* **A47**, 110–119.
- Leedman, P. J., Faulkner-Jones, B., Cram, D. S., Harrison, P. J., West, J., O'Brien, E., Simpson, R., Coppel, R. L. & Harrison, L. C. (1993). *Proc. Natl Acad. Sci. USA*, **90**, 5994–5998.
- Nakamura, F., Pudas, R., Heikkinen, O., Permi, P., Kilpeläinen, I., Munday, A. D., Hartwig, J. H., Stossel, T. P. & Ylanne, J. (2006). *Blood*, **107**, 1925–1932.
- Peutz-Kootstra, C. J., Hansen, K., De Heer, E., Abrass, C. K. & Bruijn, J. A. (2000). *J. Pathol.* **192**, 404–412.
- Popowicz, G. M., Schleicher, M., Noegel, A. A. & Holak, T. A. (2006). *Trends Biochem. Sci.* **31**, 411–419.
- Pudas, R., Kiema, T. R., Butler, P. J., Stewart, M. & Ylanne, J. (2005). *Structure*, **13**, 111–119.
- Robertson, S. P., Twigg, S. R., Sutherland-Smith, A. J., Biancalana, V., Gorlin, R. J., Horn, D., Kenwright, S. J., Kim, C. A., Morava, E., Newbury-Ecob, R., Orstavik, K. H., Quarrell, O. W., Schwartz, C. E., Shears, D. J., Suri, M., Kendrick-Jones, J. & Wilkie, A. O. (2003). *Nature Genet.* **33**, 487–491.
- Shizuta, Y., Shizuta, H., Gallo, M., Davies, P. & Pastan, I. (1976). *J. Biol. Chem.* **251**, 6562–6567.
- Takafuta, T., Wu, G., Murphy, G. F. & Shapiro, S. S. (1998). *J. Biol. Chem.* **273**, 17531–17538.
- Taveau, M., Bourg, N., Sillon, G., Roudaut, C., Bartoli, M. & Richard, I. (2003). *Mol. Cell. Biol.* **23**, 9127–9135.
- Wang, K., Ash, J. F. & Singer, S. J. (1975). *Proc. Natl Acad. Sci. USA*, **72**, 4483–4486.
- Weihing, R. R. (1988). *Biochemistry*, **27**, 1865–1869.
- Xie, Z., Xu, W., Davie, E. W. & Chung, D. W. (1998). *Biochem. Biophys. Res. Commun.* **251**, 914–919.
- Yamamoto, T., Sato, T. & Sugita, H. (1987). *Neurology*, **37**, 1329–1333.
- Zenker, M., Rauch, A., Winterpacht, A., Tagariello, A., Kraus, C., Rupprecht, T., Sticht, H. & Reis, A. (2004). *Am. J. Hum. Genet.* **74**, 731–737.